financetom
Business
financetom
/
Business
/
Amedisys and UnitedHealth Extend Merger Deadline - What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amedisys and UnitedHealth Extend Merger Deadline - What's Going On?
Dec 27, 2024 8:27 AM

Amedisys Inc ( AMED ) shares are trading higher on Friday after the company announced it extended its merger deadline with UnitedHealth Group Incorporated ( UNH ) .

In an exchange filing, the companies entered into a waiver agreement, further advancing their merger deal, originally announced on June 26, 2023.

Under the terms of the agreement, Merger Sub, a wholly owned subsidiary of UnitedHealth ( UNH ), will merge with Amedisys ( AMED ), with Amedisys ( AMED ) continuing to operate as a subsidiary of UnitedHealth Group ( UNH ).

The companies have agreed to push their $3.3 billion merger deadline to next year. This extension follows intense scrutiny from the U.S. Department of Justice, Reuters reports.

Over a month ago, the DOJ and three U.S. states filed a lawsuit to prevent the deal. They argued that the merger would harm competition in the home health services market.

Also Read: Amedisys ( AMED ), Rigetti Computing And Other Big Stocks Moving Higher On Friday

The waiver allows both Amedisys ( AMED ) and UnitedHealth Group ( UNH ) to extend the period during which they cannot terminate the merger due to delays.

The companies have agreed to waive their right to terminate the agreement until the earlier of two conditions: 5:00 p.m. New York time on the tenth business day after a final order from the U.S. District Court for the District of Maryland permanently blocking the merger, or 11:59 p.m. on December 31, 2025.

The waiver ensures that the merger process remains in effect until one of these deadlines is reached.

The waiver also includes important financial and operational adjustments. The Regulatory Break Fee under the merger agreement is set at $275 million, which could increase to $325 million if certain divestiture milestones are not met.

Additionally, the waiver modifies certain operational restrictions and closing conditions, particularly those related to government approvals, and increases the revenue-related aspect of the "Burdensome Condition" definition.

Despite regulatory scrutiny and potential challenges, this waiver marks a key development in the ongoing efforts to finalize the merger.

The companies continue to work toward completing the deal, which is expected to provide both parties substantial synergies and growth opportunities.

Price Action: UNH shares are trading lower by 0.52% to $508.47 at last check Friday. AMED is up 4.48%.

Now Read This:

Top 3 Tech And Telecom Stocks That May Rocket Higher In Q4

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Street Color: Schlumberger, Canada's Competition Bureau Reach Consent Agreement on ChampionX Takeover
--Street Color: Schlumberger, Canada's Competition Bureau Reach Consent Agreement on ChampionX Takeover
Jul 16, 2025
09:39 AM EDT, 07/16/2025 (MT Newswires) -- Price: 35.12, Change: +0.04, Percent Change: +0.11 ...
Oncolytics Biotech Says Pelareorep Data Showed Effectiveness Across Multiple Tumor Types
Oncolytics Biotech Says Pelareorep Data Showed Effectiveness Across Multiple Tumor Types
Jul 16, 2025
09:43 AM EDT, 07/16/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types. The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said. Oncolytics Biotech ( ONCY ) added that the...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Citius Oncology Prices Public Offering at $1.32 a Share
Citius Oncology Prices Public Offering at $1.32 a Share
Jul 16, 2025
09:45 AM EDT, 07/16/2025 (MT Newswires) -- Citius Oncology ( CTOR ) said Wednesday that it priced its reasonable best-efforts public offering of about 6.8 million common shares and warrants to purchase common shares at $1.32 per share, for total proceeds of about $9 million. The company said the warrants are immediately exercisable for $1.32 per share and will expire...
Copyright 2023-2026 - www.financetom.com All Rights Reserved